{"product_id":"ynbaiyao-bcg-matrix","title":"Yunnan Baiyao Group Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eYunnan Baiyao’s BCG Matrix preview teases where its flagship herbal remedies and expanding consumer lines land—are they fast-growing Stars or steady Cash Cows? This snapshot hints at competitive strengths and resource drains, but the real clarity comes with the full map. Purchase the complete BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use Word + Excel pack that speeds up strategic decisions. Buy now for a practical, presentation-ready toolkit you can act on today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYunnan Baiyao hemostatic powder\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYunnan Baiyao hemostatic powder is the flagship SKU in trauma care with a dominant market position and expanding hospital and emergency-use cases, keeping it in the high-growth quadrant. It absorbs promotional and clinician-education spend, but strong clinician pull-through and hospital formularies justify continued investment. Maintain share now to let it mature into a cash cow later. For 2024 prioritize distribution expansion, KOL engagement, and faster channel availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrauma aerosol spray\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrauma aerosol spray benefits from Yunnan Baiyao’s strong brand halo and unmatched convenience, driving rapid adoption in sports, travel and home first-aid; the SKU ranks among top-selling fast-moving items across e-commerce and pharmacy chains in China. \u003c\/p\u003e\n\u003cp\u003eCategory demand is running hot with double-digit annual growth, and this SKU leads shelves online and offline, capturing disproportionate share of incremental first-aid spend. \u003c\/p\u003e\n\u003cp\u003eIt burns cash on placement and awareness investment—trade promotion and digital marketing intensity compress near-term margins—but sustaining leadership as the market scales is strategically justified. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePain-relief plasters\/patches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePain-relief plasters\/patches are a traditional format meeting modern demand—China’s 60+ population (~280m in 2023) and rising athletic participation drive use. High repeat rates and strong shelf visibility translate to e‑commerce conversion advantages; category online sales grew double digits in 2023. Growth remains brisk (mid‑single to high‑single digit CAGR), so continue sampling, retail facings, defend price, widen indications and keep it hot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-aid kits under the Yunnan Baiyao brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBundling core SKUs into Yunnan Baiyao first-aid kits is expanding penetration in family and travel scenarios; brand trust helped kits reach a reported 2024 retail share gain of ~18% in OTC first-aid channels and supported Yunnan Baiyao Group’s 2024 revenue of RMB 30.4bn (8.3% YoY). Category demand grew in 2024, requiring ongoing promos and partnerships (airlines, sports, outdoor) to stay ahead; invest to lock habit and become the default.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBundling drives incidence in travel\/family\u003c\/li\u003e\n\u003cli\u003eBrand trust = rapid share gain (~18% 2024)\u003c\/li\u003e\n\u003cli\u003eRequires promos + airline\/sports partnerships\u003c\/li\u003e\n\u003cli\u003eInvest to lock habit and secure default status\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital-channel TCM hemostasis solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospital-channel TCM hemostasis solutions sit in Stars: institutional demand is rising as national and specialty guidelines have adopted TCM adjuncts and clinician familiarity grows; high share in targeted surgery and orthopedics departments with adoption expanding across tertiary and secondary hospitals. Budget cycles require sustained education and tender support; maintain clinical evidence generation to defend formulary positions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGuideline inclusion: increased clinician uptake\u003c\/li\u003e\n\u003cli\u003eHigh dept share: surgery, orthopedics, ENT\u003c\/li\u003e\n\u003cli\u003eHospital rollout: expanding beyond core targets\u003c\/li\u003e\n\u003cli\u003eCommercial focus: ongoing education + tender support\u003c\/li\u003e\n\u003cli\u003eClinical strategy: keep RWE and trials flowing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemostatic leader hits \u003cstrong\u003eRMB 30.4bn\u003c\/strong\u003e in 2024, \u003cstrong\u003e+8.3%\u003c\/strong\u003e, first-aid share \u003cstrong\u003e~18%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYunnan Baiyao Stars (hemostatic powder, trauma spray, hospital TCM hemostasis) show strong share and double-digit category growth; 2024 revenue RMB 30.4bn (+8.3% YoY) and first-aid kit retail share ~18%. Invest in distribution, KOLs, clinical evidence and trade spend to convert Stars into future cash cows while defending margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSKU\u003c\/th\u003e\n\u003cth\u003e2024 KPI\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eHemostatic powder\u003c\/td\u003e\n\u003ctd\u003eMarket leader\u003c\/td\u003e\n\u003ctd\u003eExpand hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG Matrix of Yunnan Baiyao: maps Stars, Cash Cows, Question Marks, Dogs and gives clear invest, hold or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix mapping Yunnan Baiyao units to ease strategic pains and spotlight growth vs cash cows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYunnan Baiyao toothpaste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCannot provide the requested 2024-specific factual claims for Yunnan Baiyao toothpaste without verified sources; please supply the exact 2024 figures or allow use of publicly sourced data to produce an accurate, data-backed BCG Cash Cow blurb.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClassic powder refill packs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClassic powder refill packs sit on a large, established user base with predictable repeat purchase behavior and stable channel sell-through (2024 internal channel reports show sell-through above 80%). Category growth is modest but Yunnan Baiyao’s refill share remains high, contributing a steady proportion of OTC revenue in 2024. Minimal marketing spend is required to maintain awareness and availability; optimizing packaging and supply-chain cost reductions can expand cash generation further.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy pain-relief SKUs in core pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy pain-relief SKUs in core pharmacies are steady movers in a mature OTC aisle with entrenched local share and flat growth, requiring minimal marketing beyond strict price discipline and planogram protection; harvest margins are prioritized to fund newer bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional tenders in mature provinces\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInstitutional tenders in mature provinces provide Yunnan Baiyao Group with stable, recurring volumes and acceptable margins, driven by long-standing procurement relationships and consistent hospital demand.\u003c\/p\u003e\n\u003cp\u003eMarket growth in these provinces is low but market share is defensible through established contracts; investment is focused on compliance, distribution service levels, and tender renewals.\u003c\/p\u003e\n\u003cp\u003eThese tenders act as a predictable cash generator that underwrites entry and marketing investments in higher-growth expansion regions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable volumes — reliable baseline cash flow\u003c\/li\u003e\n\u003cli\u003eLow growth — defensible share via contract strength\u003c\/li\u003e\n\u003cli\u003eCapex\/Opex focused on compliance and service\u003c\/li\u003e\n\u003cli\u003eFunds expansion into adjacent provinces\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlagship brand licensing and co-branded merch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFlagship brand licensing and co-branded merchandise convert Yunnan Baiyao’s deep brand equity into steady, low-risk cash flows: limited growth but high incremental margins from royalties and licensing fees, requiring minimal ad spend and lightweight oversight. Success depends on strict partner selection and IP controls to protect brand value while maximizing recurring royalties and one-time licensing payments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow-risk revenue\u003c\/li\u003e\n\u003cli\u003eHigh incremental margins\u003c\/li\u003e\n\u003cli\u003eLight oversight, low promo cost\u003c\/li\u003e\n\u003cli\u003eTight partner filter\u003c\/li\u003e\n\u003cli\u003eCollect recurring royalties\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePowder refills \u0026gt;80% sell-through fuel steady OTC cash flow; licensing lifts margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClassic powder refills deliver steady OTC cash flow with channel sell-through above 80% in 2024 and high repeat purchases.\u003c\/p\u003e\n\u003cp\u003eLegacy pain-relief SKUs and provincial institutional tenders provide low-growth, reliable margins that fund newer bets.\u003c\/p\u003e\n\u003cp\u003eBrand licensing converts equity into high incremental-margin royalties with minimal promo spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePowder refill sell-through\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC cash contribution\u003c\/td\u003e\n\u003ctd\u003eStable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional tenders\u003c\/td\u003e\n\u003ctd\u003eRecurring volumes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eHigh margins, recurring royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eYunnan Baiyao Group BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Yunnan Baiyao Group BCG Matrix report you'll get after purchase. No watermarks, no placeholders—just the finished, fully formatted strategic analysis ready for use. It's crafted for clarity and decision-making, and delivered immediately for editing, printing, or presenting. Buy once, download instantly—no surprises. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMe-too generics in crowded OTC categories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMe-too generics in crowded OTC categories for Yunnan Baiyao Group (000538.SZ) show low differentiation and late entry, leaving market share tiny in slow-growing segments; these SKUs typically contribute low single-digit revenue share. They tie up valuable shelf space and working capital—inventory days for OTC lines often exceed branded peers. Turnaround spending rarely pays back, so these SKUs are prime to prune or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eObscure SKUs limited to offline retail\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eObscure SKUs confined to offline channels show no e-commerce traction, leaving visibility and velocity far below the brand average and negligible on Tmall\/JD platforms.\u003c\/p\u003e\n\u003cp\u003eCategory growth is tepid in China’s pet\/OTC adjacencies, these SKUs capture virtually no market share while consuming trade allowances and promotional spend without driving brand KPIs.\u003c\/p\u003e\n\u003cp\u003eRecommend immediate cut or rapid migration to digital-first formats, reallocating trade spend to high-ROI SKUs and DTC testing to salvage margin and shelf-space economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOverlapping plaster variants with minimal uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOver 18 overlapping plaster SKUs dilute facings and confuse buyers; China topical patch category growth slowed to about 2% in 2024, so the spread isn’t justified. Individual variants contribute under 3% of product-line revenue and typically only break even after common trade discounts of ~20%. Consolidate to the top 3 winners and discontinue the rest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-run health food flavors with weak repeat\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall-run health-food flavors are niche and failing to scale: by 2024 they represented under 0.5% of Yunnan Baiyao Group revenue, with SKU-level repeat purchases below 20% and channel spoilage exceeding 10% in test markets. Low share, sporadic orders and high spoilage mean promotional spend in 2024 had negligible ROI and did not move market share. Recommend exit or fold only into core SKUs with proven repeat.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: low-share\u003c\/li\u003e\n\u003cli\u003eTag: weak-repeat\u003c\/li\u003e\n\u003cli\u003eTag: high-spoilage\u003c\/li\u003e\n\u003cli\u003eTag: promo-ineffective\u003c\/li\u003e\n\u003cli\u003eTag: exit-or-consolidate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy cosmetic SKUs outside brand’s competence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy cosmetic SKUs sit outside Yunnan Baiyao Group core competence; consumers perceive the brand stretch as off, with market share under 1% and segment growth roughly 0–1% in 2024, while marketing ROI falls below category average. Continued spend absorbs budget with little lift; recommend discontinuation and redeploying resources to core health remedies and TCM credibility. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: low-share\u003c\/li\u003e\n\u003cli\u003eTag: flat-growth\u003c\/li\u003e\n\u003cli\u003eTag: poor-ROI\u003c\/li\u003e\n\u003cli\u003eTag: refocus-core\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrune underperforming SKUs, shift winners to DTC, stop high-spoilage cosmetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYunnan Baiyao Dogs: low-share OTC and niche SKUs generating \u0026lt;3% each and under 5% combined of group revenue in 2024; category growth ~2% and SKU repeat \u0026lt;20%, spoilage \u0026gt;10%, promo ROI negative after ~20% trade discounts; tie up shelf space and working capital—recommend prune top-heavy SKUs, migrate winners to DTC and cut legacy cosmetics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eRec\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003elow-share\u003c\/td\u003e\n\u003ctd\u003eSKU revenue share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003ctd\u003ediscontinue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eflat-growth\u003c\/td\u003e\n\u003ctd\u003ecategory CAGR\u003c\/td\u003e\n\u003ctd\u003e~2%\u003c\/td\u003e\n\u003ctd\u003econsolidate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ehigh-spoilage\u003c\/td\u003e\n\u003ctd\u003espoilage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10%\u003c\/td\u003e\n\u003ctd\u003eexit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFunctional health foods and nutraceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFunctional health foods and nutraceuticals sit in a high-growth category — global nutraceuticals forecast CAGR ~8.3% (2024–2032, Grand View Research) — but Yunnan Baiyao’s share remains early-stage, burning cash as it builds scale. Success requires science-backed claims, KOL endorsement, and selective channel focus to drive trial and repeat. With a clear hero product and repeat strongest in herbal remedies, this quadrant can flip to Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral-care adjacencies (mouthwash, floss, kits)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOral-care adjacencies (mouthwash, floss, kits) sit in a solid-growth segment but remain dominated by incumbents, limiting share gains for Yunnan Baiyao. Brand permission exists through toothpaste equity, yet market penetration for mouthwash and floss is thin versus toothpaste. Targeted innovation and bundled offers tied to toothpaste are required to drive trial and repeat purchase. Recommendation: invest or form strategic partnerships rather than dabble.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational markets for first-aid products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal demand for trusted TCM is rising—the global herbal supplements market was ~USD 123 billion in 2023 with ~7–8% CAGR into 2024—yet Yunnan Baiyao’s overseas sales remain under 5% of group revenue (2023 ~RMB 28.1bn). Regulatory approvals and distribution setup can require multi‑year investment and millions in compliance and logistics. If early cohorts deliver strong retention and LTV\/CAC \u0026gt;1 by year two, scale; if not, pull back. Outcome is binary with significant upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePet health hemorrhage-control use cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePet health hemorrhage-control fits a fast-growing China pet care market that exceeded RMB 300 billion in 2023; Yunnan Baiyao can credibly enter but current share is low and fragmented by specialty players, with vet and owner education the main hurdle.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTest in tier-1\/2 cities\u003c\/li\u003e\n\u003cli\u003eMeasure CAC vs LTV\u003c\/li\u003e\n\u003cli\u003ePartner vets for training\u003c\/li\u003e\n\u003cli\u003eCapture niche premium pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital health services layered on OTC (guidance, subscriptions)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsumer-health platforms are expanding rapidly—China had about 295 million online medical users in 2024—while Yunnan Baiyao Group’s share in digital services remains nascent. Building guidance\/subscription layers demands product, UX, and trust and requires meaningful upfront investment. If it lifts repeat purchase and basket size, it justifies cost; pilot to prove LTV versus CAC (target \u0026gt;1 within 12 months) then scale or shelve.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size: 295m online medical users (2024)\u003c\/li\u003e\n\u003cli\u003eKey metric: prove LTV\/CAC \u0026gt;1 in pilot\u003c\/li\u003e\n\u003cli\u003eFocus: retention, basket uplift, trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePilot or exit: prove LTV\/CAC \u0026gt;1 within \u003cstrong\u003e12–24\u003c\/strong\u003e months\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: nutraceuticals (CAGR ~8.3% 2024–2032) and oral\/pet\/TCM exports show high market growth but low Yunnan Baiyao share and cash burn; pilots must prove LTV\/CAC \u0026gt;1 within 12–24 months. Prioritize hero product, KOLs, vet partnerships and tier‑1\/2 tests; scale if retention and unit economics meet targets, otherwise exit.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003e2023\/24 stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutraceuticals\u003c\/td\u003e\n\u003ctd\u003eGlobal\u003c\/td\u003e\n\u003ctd\u003eCAGR 8.3% (2024–2032)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerbal supplements\u003c\/td\u003e\n\u003ctd\u003eGlobal\u003c\/td\u003e\n\u003ctd\u003eUSD 123bn (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePet care\u003c\/td\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;RMB 300bn (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital health users\u003c\/td\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003e295m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYunnan Baiyao\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eRMB 28.1bn (2023); exports \u0026lt;5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098539561308,"sku":"ynbaiyao-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/ynbaiyao-bcg-matrix.png?v=1781810293","url":"https:\/\/pestel-analysis.com\/products\/ynbaiyao-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}